Corrections:

Haibing Xiao^1,2,*, Jin Zeng^1,2,*, Heng Li^1,2, Ke Chen^1,2, Gan Yu^1,2, Junhui Hu^1,2, Kun Tang^1,2, Hui Zhou^1,2, Qihong Huang³, Anping Li³, Yi Li^1,2, Zhangqun Ye^1,2, Ji Wang⁴ and Hua Xu^1,2

¹ Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
² Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
³ The Wistar Institute, Philadelphia, PA, USA
⁴ Department of Cell Death and Cancer Genetics, The Hormel Institute, University of Minnesota, Austin, MN, USA
^* Haibing Xiao and Jin Zeng contributed equally to this work

Published: December 24, 2019

This article has been corrected: Due to errors in image selection, two small pictures were partially overlapped in Figure 3A - the mimics-NC are the same as the inhibitor-NC in the migration group of 786-O. The corrected Figure 3 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:13201–13215. DOI: https://doi.org/10.18632/oncotarget.3915.

Figure 3: miR-1 attenuates ccRC cell migration and invasion. (A. a) Migration and invasion assay for renal cancer cells. Representative photographs were taken at ×200 magnification; number of migrated cells was quantified in ten random images from each treatment group. (b) Results were the mean ± SEM from two independent experiments and plotted as percent (%) migrating cells relative to mimic-NC or inhibitor-NC. *P < 0.05. (B) EMT-related proteins were determined by immunoblot analysis. β-Tubulin was used as loading control. (C) Representative photographs of immunofluorescence were taken at ×200 magnification. ACHN cells were transfected with 100 nM of indicated small RNA molecules.